Betting on a longevity company? See who’s really ahead before you pick a side

Updated October 202670+ pagesPDF

Longevity: Who’s Ahead
Cover of NewMarketPitch's Longevity: Who’s Ahead report, 2026 edition
Will dogs get a drug approved to extend life before people do? Very likely. Loyal’s pill for older dogs has 2 of the 3 parts of its FDA file accepted. For people, there is no path yet: the FDA does not treat aging as a disease. Chart from NewMarketPitch's Longevity report.
Neko or Function: who leads the longevity checkup? Function on people, 500,000+ members, and on sales, ~$100M (an estimate). Neko on money, $960M raised and a ~$7B value. Chart from NewMarketPitch's Longevity report.
Who is ahead in the race to reprogram human cells? Life Biosciences, not the richest lab. It dosed the first person in 2026 and shared early data. Altos and NewLimit are not in people yet. Chart from NewMarketPitch's Longevity report.
Is Neko Health, the body-scan startup, really worth $7 billion? Not on sales, mostly on promise. Neko sold ~$16M of body scans in 2025 and lost ~$70M. At ~$7B, it is valued at 430 times its sales. Chart from NewMarketPitch's Longevity report.
Do full-body scans find far more scares than cancers? Yes. In the latest review of 17 studies, 78 of 100 people scanned had a finding and ~15 needed more tests for something that was not cancer. ~1 had a cancer. Chart from NewMarketPitch's Longevity report.
How expensive are longevity companies, measured by sales? Very, in private rounds. Neko Health is valued at ~430 times its 2025 sales. The GLP-1 giants, Novo and Lilly, trade at 3.5 and 14 times. Chart from NewMarketPitch's Longevity report.
How many drugs are approved to treat aging itself? None, the FDA does not treat aging as a disease. Yet billions went into the hunt, from Altos Labs’ $3B to $1.65B for aging-drug startups recently. Chart from NewMarketPitch's Longevity report.
Do a few longevity startups take most of the money? Yes. Neko, NewLimit and Function took 51% of the $3.75B raised by longevity startups recently. The top ten took 71%. Chart from NewMarketPitch's Longevity report.
Are clinics and supplements selling longevity without proof? Yes. No longevity clinic or supplement has shown in a trial that it adds healthy years. GLP-1s cut deaths, but only in people with heart disease. Chart from NewMarketPitch's Longevity report.

70+ pages in the full report

Swipe· 70+ pages in the report

Inside the report

  • Who’s ahead, and who’s falling behind
  • How far the challengers are behind
  • Who has real data, who only promises
  • What technologies are gaining traction
  • Who are the top companies today
  • What are their valuations
  • Who’s getting funded, and by whom
  • Which business models are winning
  • What are the biggest unsolved problems
  • What has changed in the last 12 months
  • Where are the biggest opportunities
  • Who are the likely future winners
$99$79one-time payment
Get the report

Verified data with sourcesUpdated in October 2026